Compare Northrop Grumman Corporation (NOC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Northrop Grumman Corporation trades at $510.06 (market cap $74.42B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Northrop Grumman Corporation is far larger — about 48.6× Recursion Pharmaceuticals Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NOC | RXRX | |
|---|---|---|
Market Cap | $74.42B | $1.53B |
Sector | Industrials | Health |
52-Week High | $768.02 | $6.79 |
52-Week Low | $496.02 | $2.84 |
Enterprise Value | $88.65B | $946.50M |
Dividend Yield | 1.79% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
